Last reviewed · How we verify
IPG7236
At a glance
| Generic name | IPG7236 |
|---|---|
| Sponsor | Nanjing Immunophage Biotech Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Orally Administered IPG7236 in Healthy Adult Participants (PHASE1)
- Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IPG7236 CI brief — competitive landscape report
- IPG7236 updates RSS · CI watch RSS
- Nanjing Immunophage Biotech Co., Ltd portfolio CI